Consensus Ocugen, Inc.

Equities

OCGN

US67577C1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
1.71 ^USD	-2.29%		-7.57%	+197.39%

May. 15	Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study	MT
May. 15	Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy	CI

Evolution of the average Target Price on Ocugen, Inc.

Price target over the last 5 years

History of analyst recommendation changes

14a415627f9a550cb0fb8678e558cf9.Hh-Cve0CerWpwdp8CTVogC_cElOuPEPFe4RGHNiXVtg.KVjm6pREEseZkooGeX4ptUK7IhTgfwGiDMk0dq3aHpx1SLHpj0sS29OgsQ~8bb12b44e3ccabbb224a9932b5cec192

Analyst Recommendations on Ocugen, Inc.

Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	Apr. 22	MT
Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	Apr. 22	MT
HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating	Jan. 24	MT
Cantor Fitzgerald Adjusts Ocugen's Price Target to $2 From $2.50, Keeps Overweight Rating	23-08-31	MT
Chardan Research Raises Ocugen's Price Target to $4 From $3.50, Buy Rating Kept	23-05-08	MT
Chardan Upgrades Ocugen to Buy From Neutral, Citing Recent Sell-Off	23-03-01	MT
Mizuho Adjusts Price Target on Ocugen to $3 From $5, Maintains Buy Rating	23-03-01	MT
Mizuho Securities Starts Ocugen at Buy With $5 Price Target	22-08-23	MT
HC Wainwright Adjusts Ocugen's Price Target to $6 from $7, Maintains Buy Rating	22-08-15	MT
Roth Capital Reinstates Ocugen at Buy with $8 Price Target	22-06-15	MT
Cantor Fitzgerald Starts Ocugen at Overweight With $4.50 Price Target	22-06-02	MT
Chardan Trims Ocugen's Price Targe to $3.50 From $4, Maintains Neutral Rating	22-05-09	MT
Chardan Research Adjusts Ocugen's Price Target to $3.50 From $4, Maintains Neutral Rating	22-05-09	MT
HC Wainwright Adjusts Ocugen's Price Target to $8 from $10, Maintains Buy Rating	22-02-28	MT
ANALYST RECOMMENDATIONS : Alliant Energy, Ally Financial, Alphabet, HSBC, Honest...	21-06-14
OCUGEN : Cantor Fitzgerald Adjusts Ocugen PT to $4 From $11, Maintains Neutral Rating	21-06-11	MT
OCUGEN : Chardan Adjusts Ocugen PT to $4.50 From $8, Maintains Neutral Rating	21-06-11	MT
OCUGEN : HC Wainwright Adjusts Ocugen's Price Target to $10 From $12, Maintains Buy Rating	21-06-11	MT
OCUGEN : Roth Capital Cuts Ocugen to Neutral From Buy, Price Target to $6 From $10	21-06-11	MT
OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating	21-05-10	MT
TODAY'S ANALYST RECOMMENDATIONS : Oracle, Facebook, Berkeley, Acushnet, Ocugen, London Stock Exchange, Flutter...	21-05-10
OCUGEN : Cantor Fitzgerald Downgrades Ocugen to Neutral From Overweight, Adjusts PT to $11 From $15	21-05-07	MT
Ocugen : Bharat Biotech Two-Dose COVID-19 Vaccine Candidate Shows 78% Efficacy Rate	21-04-21	MT
OCUGEN : Cantor Fitzgerald Adjusts Ocugen PT to $15 From $4, Maintains Overweight Rating	21-03-03	MT
OCUGEN : Chardan Capital Downgrades Ocugen to Neutral From Buy on Valuation, Adjusts Price Target to $13 From $0.70	21-02-09	MT